Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2004 Jul;59(7):602–607. doi: 10.1136/thx.2003.018044

Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer

M Janssen-Heijnen 1, S Smulders 1, V Lemmens 1, F Smeenk 1, H J A A van Geffen 1, J Coebergh 1
PMCID: PMC1747080  PMID: 15223870

Abstract

Background: With the rising mean age, more patients will be diagnosed with one or more other serious diseases at the time of lung cancer diagnosis. Little is known about the best way to treat elderly patients with comorbidity or the outcome of treatment. This study was undertaken to evaluate the independent effects of age and comorbidity on treatment and prognosis in patients with non-small cell lung cancer (NSCLC).

Methods: All patients with NSCLC diagnosed between 1995 and 1999 in the southern part of the Netherlands (n = 4072) were included.

Results: The proportion of patients with localised NSCLC who underwent surgery was 92% in patients younger than 60 years and 9% in those aged 80 years or older. In patients aged 60–79 years this proportion also decreased with comorbidity. In patients with non-localised NSCLC the proportion receiving chemotherapy was considerably higher for those aged less than 60 years (24%) than in those aged 80 or older (2%). The number of comorbid conditions had no significant influence on the treatment chosen for patients with non-localised disease. Multivariable survival analyses showed that age, tumour size, and treatment were independent prognostic factors for patients with localised disease, and stage of disease and treatment for those with non-localised disease. Comorbidity had no independent prognostic effect.

Conclusions: It is questionable whether the less aggressive treatment of elderly patients with NSCLC is justified.

Full Text

The Full Text of this article is available as a PDF (93.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexiou Christos, Beggs David, Onyeaka Patrick, Kotidis Kostas, Ghosh Sudip, Beggs Lynda, Hopkinson David N., Duffy John P., Morgan W. Ellis, Rocco Gaetano. Pneumonectomy for stage I (T1N0 and T2N0) nonsmall cell lung cancer has potent, adverse impact on survival. Ann Thorac Surg. 2003 Oct;76(4):1023–1028. doi: 10.1016/s0003-4975(03)00883-x. [DOI] [PubMed] [Google Scholar]
  2. Battafarano Richard J., Piccirillo Jay F., Meyers Bryan F., Hsu Han-Shui, Guthrie Tracey J., Cooper Joel D., Patterson G. Alexander. Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002 Feb;123(2):280–287. doi: 10.1067/mtc.2002.119338. [DOI] [PubMed] [Google Scholar]
  3. Bolliger C. T., Jordan P., Solèr M., Stulz P., Grädel E., Skarvan K., Elsasser S., Gonon M., Wyser C., Tamm M. Exercise capacity as a predictor of postoperative complications in lung resection candidates. Am J Respir Crit Care Med. 1995 May;151(5):1472–1480. doi: 10.1164/ajrccm.151.5.7735602. [DOI] [PubMed] [Google Scholar]
  4. Charlson M. E., Pompei P., Ales K. L., MacKenzie C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8. [DOI] [PubMed] [Google Scholar]
  5. Damhuis R. A., Schütte P. R. Resection rates and postoperative mortality in 7,899 patients with lung cancer. Eur Respir J. 1996 Jan;9(1):7–10. doi: 10.1183/09031936.96.09010007. [DOI] [PubMed] [Google Scholar]
  6. De Marco M. F., Janssen-Heijnen M. L., van der Heijden L. H., Coebergh J. W. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer. 2000 Jan;36(1):95–99. doi: 10.1016/s0959-8049(99)00221-x. [DOI] [PubMed] [Google Scholar]
  7. Eberly Lynn E., Ockene Judith, Sherwin Roger, Yang Lingfeng, Kuller Lewis, Multiple Risk Factor Intervention Trial Research Group Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters. Int J Epidemiol. 2003 Aug;32(4):592–599. doi: 10.1093/ije/dyg177. [DOI] [PubMed] [Google Scholar]
  8. Extermann M., Overcash J., Lyman G. H., Parr J., Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998 Apr;16(4):1582–1587. doi: 10.1200/JCO.1998.16.4.1582. [DOI] [PubMed] [Google Scholar]
  9. Finlayson E. V., Birkmeyer J. D. Operative mortality with elective surgery in older adults. Eff Clin Pract. 2001 Jul-Aug;4(4):172–177. [PubMed] [Google Scholar]
  10. Firat Selim, Bousamra Michael, Gore Elizabeth, Byhardt Roger W. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1047–1057. doi: 10.1016/s0360-3016(01)02741-9. [DOI] [PubMed] [Google Scholar]
  11. Firat Selim, Byhardt Roger W., Gore Elizabeth. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):357–364. doi: 10.1016/s0360-3016(02)02939-5. [DOI] [PubMed] [Google Scholar]
  12. Greenfield S., Aronow H. U., Elashoff R. M., Watanabe D. Flaws in mortality data. The hazards of ignoring comorbid disease. JAMA. 1988 Oct 21;260(15):2253–2255. [PubMed] [Google Scholar]
  13. Gridelli Cesare, Perrone Francesco, Gallo Ciro, Cigolari Silvio, Rossi Antonio, Piantedosi Francovito, Barbera Santi, Ferraù Francesco, Piazza Elena, Rosetti Francesco. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003 Mar 5;95(5):362–372. doi: 10.1093/jnci/95.5.362. [DOI] [PubMed] [Google Scholar]
  14. Guadagnoli E., Weitberg A., Mor V., Silliman R. A., Glicksman A. S., Cummings F. J. The influence of patient age on the diagnosis and treatment of lung and colorectal cancer. Arch Intern Med. 1990 Jul;150(7):1485–1490. [PubMed] [Google Scholar]
  15. Hakulinen T., Abeywickrama K. H. A computer program package for relative survival analysis. Comput Programs Biomed. 1985;19(2-3):197–207. doi: 10.1016/0010-468x(85)90011-x. [DOI] [PubMed] [Google Scholar]
  16. Janssen-Heijnen M. L., Schipper R. M., Razenberg P. P., Crommelin M. A., Coebergh J. W. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998 Aug;21(2):105–113. doi: 10.1016/s0169-5002(98)00039-7. [DOI] [PubMed] [Google Scholar]
  17. Kaplan M. H., Feinstein A. R. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974 Sep;27(7-8):387–404. doi: 10.1016/0021-9681(74)90017-4. [DOI] [PubMed] [Google Scholar]
  18. Lash Timothy L., Thwin Soe Soe, Horton Nicholas J., Guadagnoli Edward, Silliman Rebecca A. Multiple informants: a new method to assess breast cancer patients' comorbidity. Am J Epidemiol. 2003 Feb 1;157(3):249–257. doi: 10.1093/aje/kwf193. [DOI] [PubMed] [Google Scholar]
  19. Miller M. D., Paradis C. F., Houck P. R., Mazumdar S., Stack J. A., Rifai A. H., Mulsant B., Reynolds C. F., 3rd Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992 Mar;41(3):237–248. doi: 10.1016/0165-1781(92)90005-n. [DOI] [PubMed] [Google Scholar]
  20. Monfardini S., Aapro M., Ferrucci L., Zagonel V., Scalliet P., Fentiman I. Commission of the European Communities "Europe Against Cancer" Programme. European school of oncology advisory report. Cancer treatment in the elderly. Eur J Cancer. 1993;29A(16):2325–2330. doi: 10.1016/0959-8049(93)90229-9. [DOI] [PubMed] [Google Scholar]
  21. Piccirillo J. F. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000 Apr;110(4):593–602. doi: 10.1097/00005537-200004000-00011. [DOI] [PubMed] [Google Scholar]
  22. Post P. N., Kil P. J., Hendrikx A. J., Janssen-Heijnen M. L., Crommelin M. A., Coebergh J. W. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 1999 Oct;84(6):652–656. doi: 10.1046/j.1464-410x.1999.00279.x. [DOI] [PubMed] [Google Scholar]
  23. Repetto Lazzaro, Fratino Lucia, Audisio Riccardo A., Venturino Antonella, Gianni Walter, Vercelli Marina, Parodi Stefano, Dal Lago Denise, Gioia Flora, Monfardini Silvio. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002 Jan 15;20(2):494–502. doi: 10.1200/JCO.2002.20.2.494. [DOI] [PubMed] [Google Scholar]
  24. Satariano W. A., Ragland D. R. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104–110. doi: 10.7326/0003-4819-120-2-199401150-00002. [DOI] [PubMed] [Google Scholar]
  25. Tammemagi C. Martin, Neslund-Dudas Christine, Simoff Michael, Kvale Paul. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003 Mar 1;103(6):792–802. doi: 10.1002/ijc.10882. [DOI] [PubMed] [Google Scholar]
  26. Veronesi A., Crivellari D., Magri M. D., Cartei G., Mansutti M., Foladore S., Monfardini S. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer. 1996 Sep;32A(10):1809–1811. doi: 10.1016/0959-8049(96)00190-6. [DOI] [PubMed] [Google Scholar]
  27. Wei J. Y. Cardiovascular comorbidity in the older cancer patient. Semin Oncol. 1995 Feb;22(1 Suppl 1):9–10. [PubMed] [Google Scholar]
  28. de Rijke J. M., Schouten L. J., Schouten H. C., Jager J. J., Koppejan A. G., van den Brandt P. A. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol. 1996 Sep;7(7):677–685. doi: 10.1093/oxfordjournals.annonc.a010716. [DOI] [PubMed] [Google Scholar]
  29. van Spronsen D. J., Janssen-Heijnen M. L., Breed W. P., Coebergh J. W. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999 Jul;78(7):315–319. doi: 10.1007/s002770050521. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES